Cellular and membrane-localized oxidized antioxidants

Cellular and membrane-localized oxidized antioxidants refer to the pool of endogenous antioxidant molecules, such as Vitamin E (alpha-tocopherol) and Coenzyme Q10, that have been converted to their inactive, oxidized states due to severe oxidative stress. In many mitochondrial and neurodegenerative diseases, the accumulation of these oxidized species and the depletion of their reduced counterparts lead to catastrophic lipid peroxidation and cellular dysfunction (Martinelli et al., 2012, PubMed: 22964618). Therapeutic strategies targeting these oxidized species involve the use of small-molecule redox modulators, such as Vatiquinone (EPI-743). These agents function by facilitating the re-reduction of oxidized antioxidants, thereby restoring the cell's natural defense mechanisms and stabilizing mitochondrial membranes (Shrader et al., 2011, PubMed: 21565551). This approach is particularly relevant in conditions where primary mitochondrial defects lead to excessive reactive oxygen species (ROS) production and subsequent oxidative damage (ClinicalTrials.gov, NCT01728064). By maintaining the redox state of the lipid bilayer, these drugs prevent the chain reaction of lipid peroxidation that leads to ferroptosis and cell death. Clinical applications of this target focus on rare genetic disorders like Leigh syndrome and Friedreich's ataxia.

Other names

Oxidized redox couplesOxidized lipid-soluble antioxidantsOxidized alpha-tocopherolOxidized Coenzyme Q10Oxidized alpha-tocopheryl quinone

The drugs act as catalytic electron shuttles that reduce oxidized antioxidants (such as alpha-tocopheryl quinone or oxidized Coenzyme Q10) back to their active, reduced forms, thereby restoring the cellular antioxidant capacity and mitigating oxidative damage (Shrader et al., 2011, PubMed: 21565551).